硕腾
ZTS
79.38
+0.96
+1.22%
硕腾
US · ZTS
#700 按市值排名
上市于 1970
79.38
+0.96
+1.22%
实时 - 追踪5344个代码 - 心跳于496秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了15家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 98.74% +0.07pp
- 机构数量
- 1,790 -15
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund75.63%
Private Company7.47%
Public Company5.31%
Hedge Fund5.11%
Government Pension Fund2.21%
Sovereign Wealth Fund1.16%
Family Office/Trust0.55%
VC/PE Fund0.47%
Insurance Company0.32%
Other1.78%
主要股东 截至 2026-06-30
BlackRock
9.54% · 39.43M 股
Vanguard Capital Management, LLC
6.87% · 28.39M 股
Vanguard Portfolio Management, LLC
5.77% · 23.86M 股
State Street Global Advisors
4.76% · 19.67M 股
State Farm Mutual Automobile Insurance Company
3.85% · 15.89M 股
Geode Capital Management, LLC
3.22% · 13.29M 股
Wellington Management Group
2.28% · 9.42M 股
UBS Asset Management
1.83% · 7.57M 股
Nordea Investment Management AB
1.60% · 6.59M 股
Deutsche Asset & Wealth Management
1.39% · 5.74M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 39次买入 · 7次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Kristin Peck | Chief Executive Officer | 0.03% |
| Michael McCAllister | Independent Non-Executive Chairperson | 0.01% |
| Heidi Chen | Executive VP, General Counsel, Corporate Secretary & Business Lead of Human Health Diagnostics | 0.01% |
| Robert Scully | Independent Director | 0.01% |
| Louise Parent | Independent Director | 0.01% |
| Paul Bisaro | Independent Director | 0.01% |
| Wetteny Joseph | Chief Financial Officer | 0.01% |
| Frank D'Amelio | Independent Director | 0.01% |
| Gregory Norden | Independent Director | 0.00% |
| Roxanne Lagano | Executive VP and Chief Human Resources Officer & Global Operations | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-29 | Julie Fuller | Executive VP, Chief Human Resources Officer & Global Operations | Derivative Exercise and Sale | -274 | $69.83 |
| 2026-09-29 | Julie Fuller | Executive VP, Chief Human Resources Officer & Global Operations | Derivative Exercise and Retained | +525 | -- |
| 2026-09-16 | Mark Stetter | Independent Director | Other Derivative Acquisition | +342 | -- |
| 2026-08-30 | James Saccaro | Chief Financial Officer | Other Derivative Acquisition | +81,063 | -- |
| 2026-08-06 | Frank D'Amelio | Independent Director | Other Disposition | -6,650 | -- |
| 2026-07-09 | Wetteny Joseph | Chief Financial Officer | Other Derivative Acquisition | +363 | -- |
| 2026-07-09 | Kristin Peck | Chief Executive Officer | Other Derivative Acquisition | +616 | -- |
| 2026-07-09 | Roxanne Lagano | Executive VP and Chief Human Resources Officer & Global Operations | Other Derivative Acquisition | +314 | -- |
| 2026-07-09 | Abhay Nayak | Former Executive VP and Head of Strategy, Accelerated Growth Businesses & Commercial Development | Other Derivative Acquisition | +214 | -- |
| 2026-07-09 | Julie Fuller | Executive VP, Chief Human Resources Officer & Global Operations | Other Derivative Acquisition | +314 | -- |
| 2026-07-09 | Jeannette Astorga | Executive VP of Corporate Affairs & Communications and Chief Sustainability Officer | Other Derivative Acquisition | +45 | -- |
| 2026-07-09 | Rimma Driscoll | Head of Global Strategy, Commercial & Business Development and Global BioDevices | Other Derivative Acquisition | +237 | -- |
| 2026-07-09 | Keith Sarbaugh | Executive VP & Chief Digital and Technology Officer | Other Derivative Acquisition | +259 | -- |
| 2026-07-09 | Kevin Esch | Senior Vice President of Global Therapeutics | Other Derivative Acquisition | +308 | -- |
| 2026-06-17 | Mark Stetter | Independent Director | Other Derivative Acquisition | +317 | -- |
| 2026-06-14 | Abhay Nayak | Former Executive VP and Head of Strategy, Accelerated Growth Businesses & Commercial Development | Initial Statement of Beneficial | 0 | -- |
| 2026-06-09 | Michael McCAllister | Independent Non-Executive Chairperson | Other Disposition | -1,209 | -- |
| 2026-05-20 | Mark Stetter | Independent Director | Derivative Exercise and Retained | +1,572 | -- |
| 2026-05-19 | Louise Parent | Independent Director | Derivative Exercise and Retained | +12,130 | -- |
| 2026-05-12 | Paul Bisaro | Independent Director | Open Market Acquisition | +2,000 | $75.88 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:22 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
硕腾 讨论区 0 条评论